{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:05:29Z","timestamp":1781625929609,"version":"3.54.5"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer remains a major global health challenge, with therapeutic resistance significantly limiting treatment success. Traditional approaches, including surgery, chemotherapy, and radiotherapy, often encounter barriers such as metastasis and adverse effects on healthy tissues. The Warburg effect, which describes cancer cells\u2019 reliance on glucose fermentation despite oxygen availability, has prompted investigations into alternative metabolic interventions. The ketogenic diet (KD), characterized by high fat intake and low carbohydrate intake, induces a metabolic shift that may selectively disadvantage malignant cells while preserving normal tissue function. While emerging evidence, including preclinical studies, early-phase trials, and limited clinical series, suggests that KD may help overcome treatment resistance by suppressing the PI3K\/Akt\/mTOR pathway, reducing insulin-like growth factor-1 (IGF-1) signaling, and enhancing cancer cell susceptibility to chemotherapy and targeted therapies, robust data from large, randomized controlled trials (RCTs) remain sparse. Most current findings derive primarily from animal models and small pilot studies, with definitive efficacy and safety in broad patient populations yet to be established. Preclinical and preliminary clinical studies indicate KD\u2019s potential in modulating epigenetic markers, reducing inflammation, and improving patient metabolic health. However, patient adherence remains challenging and standardized protocols are still under development. This review explores the molecular mechanisms underlying KD\u2019s anticancer effects, its role in mitigating drug resistance, and current translational insights, with emphasis on the nascent stage of high-quality clinical trial evidence and areas for future research.<\/jats:p>","DOI":"10.1186\/s12986-025-01055-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:26:23Z","timestamp":1765823183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets"],"prefix":"10.1186","volume":"23","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pezhman","family":"Shafiei Asheghabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Mashhadikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Nasirzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeganeh","family":"Ettehad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Gholamrezaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Mehdizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Zali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najma","family":"Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel J.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Entezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Taheriazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Rahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiavash","family":"Hushmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1","key":"1055_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh R, Shibue T, Dempster JM, Hahn WC, Vazquez F. The present and future of the cancer dependency map. Nat Rev Cancer. 2025;25(1):59\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1055_CR2","first-page":"443","volume":"70","author":"KD Miller","year":"2020","unstructured":"Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020;70(6):443\u201359.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1055_CR3","first-page":"1","volume":"1","author":"C Damyanov","year":"2018","unstructured":"Damyanov C, Maslev I, Pavlov V, Avramov L. Conventional treatment of cancer realities and problems. Ann Complement Altern Med. 2018;1(1):1\u20139.","journal-title":"Ann Complement Altern Med"},{"issue":"12","key":"1055_CR4","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/ERC-22-0173","volume":"29","author":"DG Hardie","year":"2022","unstructured":"Hardie DG. 100 years of the Warburg effect: a historical perspective. Endocr Relat Cancer. 2022;29(12):T1-13.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1055_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/carcin\/bgt480","volume":"35","author":"TN Seyfried","year":"2014","unstructured":"Seyfried TN, Flores RE, Poff AM, D\u2019Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3):515\u201327.","journal-title":"Carcinogenesis"},{"key":"1055_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-7075-7-7","volume":"7","author":"TN Seyfried","year":"2010","unstructured":"Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab. 2010;7:1\u201322.","journal-title":"Nutr Metab"},{"issue":"3\u20134","key":"1055_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000510839","volume":"65","author":"F Plotti","year":"2020","unstructured":"Plotti F, Terranova C, Luvero D, Bartolone M, Messina G, Feole L, et al. Diet and chemotherapy: the effects of fasting and ketogenic diet on cancer treatment. Chemotherapy. 2020;65(3\u20134):77\u201384.","journal-title":"Chemotherapy"},{"issue":"2","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000484045","volume":"25","author":"RJ Klement","year":"2018","unstructured":"Klement RJ. Fasting, fats, and physics: combining ketogenic and radiation therapy against cancer. Complement Med Res. 2018;25(2):102\u201313.","journal-title":"Complement Med Res"},{"key":"1055_CR9","doi-asserted-by":"crossref","unstructured":"Alidadi M, Banach M, Guest PC, Bo S, Jamialahmadi T, Sahebkar A, editors. The effect of caloric restriction and fasting on cancer. Seminars in Cancer Biology; 2021: Elsevier.","DOI":"10.1016\/j.semcancer.2020.09.010"},{"key":"1055_CR10","doi-asserted-by":"crossref","unstructured":"Kalamian M. The therapeutic ketogenic diet: Harnessing glucose, insulin, and ketone metabolism. Integrative and functional medical nutrition therapy: principles and practices. Springer; 2020. pp. 335\u201365.","DOI":"10.1007\/978-3-030-30730-1_22"},{"issue":"12","key":"1055_CR11","doi-asserted-by":"publisher","first-page":"e115147","DOI":"10.1371\/journal.pone.0115147","volume":"9","author":"M Lv","year":"2014","unstructured":"Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115147.","journal-title":"PLoS One"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-7075-7-74","volume":"7","author":"P Stafford","year":"2010","unstructured":"Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab. 2010;7:1\u201311.","journal-title":"Nutr Metab"},{"issue":"2","key":"1055_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/cimb43020042","volume":"43","author":"WH Talib","year":"2021","unstructured":"Talib WH, Mahmod AI, Kamal A, Rashid HM, Alashqar AMD, Khater S, et al. Ketogenic diet in cancer prevention and therapy: molecular targets and therapeutic opportunities. Curr Issues Mol Biol. 2021;43(2):558\u201389.","journal-title":"Curr Issues Mol Biol"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nutres.2025.04.010","volume":"139","author":"A Matawali","year":"2025","unstructured":"Matawali A, Yeap JW, Sulaiman SF, Tan ML. The effects of ketone bodies and ketogenesis on the PI3K\/AKT\/mTOR signaling pathway: a systematic review. Nutr Res. 2025;139:16\u201349.","journal-title":"Nutr Res"},{"issue":"2","key":"1055_CR15","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1038\/oncsis.2016.2","volume":"5","author":"RJ Klement","year":"2016","unstructured":"Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin\/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis. 2016;5(2):e193.","journal-title":"Oncogenesis"},{"issue":"4","key":"1055_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1399-0004.2011.01809.x","volume":"81","author":"R Kanwal","year":"2012","unstructured":"Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303\u201311.","journal-title":"Clin Genet"},{"key":"1055_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:1\u201316.","journal-title":"Genome Biol"},{"issue":"10","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3390\/cells9102281","volume":"9","author":"K Zappe","year":"2020","unstructured":"Zappe K, Cichna-Markl M. Aberrant DNA methylation of ABC transporters in cancer. Cells. 2020;9(10):2281.","journal-title":"Cells"},{"issue":"3","key":"1055_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403\u201318.","journal-title":"Nat Med"},{"issue":"1","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","volume":"9","author":"W Dai","year":"2024","unstructured":"Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S, et al. Epigenetics-targeted drugs: current paradigms and future challenges. Signal Transduct Target Ther. 2024;9(1):332.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1055_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","volume":"52","author":"S Yoon","year":"2016","unstructured":"Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J. 2016;52(1):1\u201311.","journal-title":"Chonnam Med J"},{"issue":"5","key":"1055_CR22","first-page":"56","volume":"3","author":"L Stephan","year":"2015","unstructured":"Stephan L, Momparler R. Combination chemotherapy of cancer using the inhibitor of DNA methylation 5-aza-2\u2019-deoxycytidine (decitabine). J Cancer Res Ther. 2015;3(5):56\u201365.","journal-title":"J Cancer Res Ther"},{"issue":"56","key":"1055_CR23","doi-asserted-by":"publisher","first-page":"96249","DOI":"10.18632\/oncotarget.21997","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Zhou C, Ni S, Wang S, Ni C, Yang P, Ye M. Methylated claudin-11 associated with metastasis and poor survival of colorectal cancer. Oncotarget. 2017;8(56):96249\u201362.","journal-title":"Oncotarget"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2017.07.082","volume":"630","author":"J Li","year":"2017","unstructured":"Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, et al. DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 2017;630:1\u20137.","journal-title":"Gene"},{"issue":"49","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"84714","DOI":"10.18632\/oncotarget.20950","volume":"8","author":"E Burgermeister","year":"2017","unstructured":"Burgermeister E, H\u00f6de P, Betge J, Gutting T, Merkel A, Wu W, et al. Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget. 2017;8(49):84714\u201328.","journal-title":"Oncotarget"},{"issue":"19","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-14-0570","volume":"20","author":"T Shimizu","year":"2014","unstructured":"Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, et al. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res. 2014;20(19):5032\u201340.","journal-title":"Clin Cancer Res"},{"key":"1055_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-018-0587-8","volume":"11","author":"W Si","year":"2019","unstructured":"Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of MicroRNAs in cancer drug resistance. Clin Epigenetics. 2019;11:1\u201324.","journal-title":"Clin Epigenetics"},{"key":"1055_CR28","doi-asserted-by":"publisher","first-page":"1495221","DOI":"10.3389\/fimmu.2024.1495221","volume":"15","author":"X Duan","year":"2024","unstructured":"Duan X, Xing Z, Qiao L, Qin S, Zhao X, Gong Y, Li X. The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front Immunol. 2024;15:1495221.","journal-title":"Front Immunol"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.acr.2022.12.002","volume":"158","author":"PC Moore","year":"2023","unstructured":"Moore PC, Henderson KW, Classon M. The epigenome and the many facets of cancer drug tolerance. Adv Cancer Res. 2023;158:1\u201339.","journal-title":"Adv Cancer Res"},{"issue":"3","key":"1055_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/cas.15681","volume":"114","author":"S Kato","year":"2023","unstructured":"Kato S, Maeda Y, Sugiyama D, Watanabe K, Nishikawa H, Hinohara K. The cancer epigenome: non-cell autonomous player in tumor immunity. Cancer Sci. 2023;114(3):730\u201340.","journal-title":"Cancer Sci"},{"issue":"3","key":"1055_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/1040841X.2019.1607248","volume":"45","author":"RC Lowrence","year":"2019","unstructured":"Lowrence RC, Subramaniapillai SG, Ulaganathan V, Nagarajan S. Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells. Crit Rev Microbiol. 2019;45(3):334\u201353.","journal-title":"Crit Rev Microbiol"},{"issue":"3","key":"1055_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/cancers6031769","volume":"6","author":"G Housman","year":"2014","unstructured":"Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers. 2014;6(3):1769\u201392.","journal-title":"Cancers"},{"issue":"10","key":"1055_CR33","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","volume":"100","author":"C Laverdi\u00e8re","year":"2002","unstructured":"Laverdi\u00e8re C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100(10):3832\u20134.","journal-title":"Blood"},{"issue":"6","key":"1055_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45(6):487\u201398.","journal-title":"Cell Prolif"},{"issue":"5684","key":"1055_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1099320","volume":"305","author":"DR Green","year":"2004","unstructured":"Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305(5684):626\u20139.","journal-title":"Science"},{"issue":"14","key":"1055_CR36","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/febs.13527","volume":"283","author":"JH Zheng","year":"2016","unstructured":"Zheng JH, Viacava Follis A, Kriwacki RW, Moldoveanu T. Discoveries and controversies in BCL-2 protein\u2010mediated apoptosis. FEBS J. 2016;283(14):2690\u2013700.","journal-title":"FEBS J"},{"issue":"5","key":"1055_CR37","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.18632\/oncotarget.6405","volume":"7","author":"H-D Um","year":"2015","unstructured":"Um H-D. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 2015;7(5):5193.","journal-title":"Oncotarget"},{"key":"1055_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-165","volume":"14","author":"J Jung","year":"2014","unstructured":"Jung J, Kim HY, Maeng J, Kim M, Shin DH, Lee K. Interaction of translationally controlled tumor protein with Apaf-1 is involved in the development of chemoresistance in HeLa cells. BMC Cancer. 2014;14:1\u201313.","journal-title":"BMC Cancer"},{"key":"1055_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00197","volume":"4","author":"P Obexer","year":"2014","unstructured":"Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197.","journal-title":"Front Oncol"},{"issue":"1","key":"1055_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/0973-1482.150407","volume":"12","author":"Y Pazhang","year":"2016","unstructured":"Pazhang Y, Jaliani HZ, Imani M, Dariushnejad H. Synergism between NF-kappa B inhibitor, celastrol, and XIAP inhibitor, embelin, in an acute myeloid leukemia cell line, HL-60. J Cancer Res Ther. 2016;12(1):155\u201360.","journal-title":"J Cancer Res Ther"},{"issue":"7115","key":"1055_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature05257","volume":"444","author":"S Rigaud","year":"2006","unstructured":"Rigaud S, Fondan\u00e8che MC, Lambert N, Pasquier B, Mateo V, Soulas P, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444(7115):110\u20134.","journal-title":"Nature"},{"issue":"34","key":"1055_CR42","doi-asserted-by":"publisher","first-page":"35829","DOI":"10.1074\/jbc.M405538200","volume":"279","author":"Z Jin","year":"2004","unstructured":"Jin Z, McDonald ER, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 2004;279(34):35829\u201339.","journal-title":"J Biol Chem"},{"issue":"28","key":"1055_CR43","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/sj.onc.1202763","volume":"18","author":"MS Sheikh","year":"1999","unstructured":"Sheikh MS, Huang Y, Fernandez-Salas EA, El-Deiry WS, Friess H, Amundson S, et al. The antiapoptotic decoy receptor TRID\/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999;18(28):4153\u20139.","journal-title":"Oncogene"},{"issue":"1","key":"1055_CR44","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3390\/cimb46010046","volume":"46","author":"K Yaacoub","year":"2024","unstructured":"Yaacoub K, Pedeux R, Lafite P, Jarry U, Aci-S\u00e8che S, Bonnet P, et al. The identification of new c-FLIP inhibitors for restoring apoptosis in TRAIL-resistant cancer cells. Curr Issues Mol Biol. 2024;46(1):710\u201328.","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"1055_CR45","doi-asserted-by":"publisher","first-page":"e46885","DOI":"10.1371\/journal.pone.0046885","volume":"7","author":"KK Ambacher","year":"2012","unstructured":"Ambacher KK, Pitzul KB, Karajgikar M, Hamilton A, Ferguson SS, Cregan SP. The JNK- and AKT\/GSK3\u03b2- signaling pathways converge to regulate Puma induction and neuronal apoptosis induced by trophic factor deprivation. PLoS One. 2012;7(10):e46885.","journal-title":"PLoS One"},{"issue":"8","key":"1055_CR46","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/bjc.2014.453","volume":"111","author":"H Ghebeh","year":"2014","unstructured":"Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, et al. Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K\/Akt pathway. Br J Cancer. 2014;111(8):1552\u201361.","journal-title":"Br J Cancer"},{"issue":"30","key":"1055_CR47","doi-asserted-by":"publisher","first-page":"49275","DOI":"10.18632\/oncotarget.17568","volume":"8","author":"M Wangpaichitr","year":"2017","unstructured":"Wangpaichitr M, Wu C, Li YY, Nguyen DJ, Kandemir H, Shah S, et al. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget. 2017;8(30):49275.","journal-title":"Oncotarget"},{"issue":"11","key":"1055_CR48","doi-asserted-by":"publisher","first-page":"e81162","DOI":"10.1371\/journal.pone.0081162","volume":"8","author":"R Marullo","year":"2013","unstructured":"Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One. 2013;8(11):e81162.","journal-title":"PLoS One"},{"key":"1055_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-015-0140-8","volume":"8","author":"LM Poisson","year":"2015","unstructured":"Poisson LM, Munkarah A, Madi H, Datta I, Hensley-Alford S, Tebbe C, et al. A metabolomic approach to identifying platinum resistance in ovarian cancer. J Ovarian Res. 2015;8:1\u201314.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1055_CR50","volume":"6","author":"M Wangpaichitr","year":"2017","unstructured":"Wangpaichitr M, Kandemir H, Li Y, Wu C, Nguyen D, Feun L, et al. Relationship of metabolic alterations and PD-L1 expression in cisplatin resistant lung cancer. Cell & developmental biology. 2017;6(2):183.","journal-title":"Cell & developmental biology"},{"key":"1055_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.freeradbiomed.2019.03.009","volume":"135","author":"A Cruz-Berm\u00fadez","year":"2019","unstructured":"Cruz-Berm\u00fadez A, Laza-Briviesca R, Vicente-Blanco RJ, Garc\u00eda-Grande A, Coronado MJ, Laine-Men\u00e9ndez S, et al. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1\u03b1 in NSCLC which can be overcome by OXPHOS inhibition. Free Radic Biol Med. 2019;135:167\u201381.","journal-title":"Free Radic Biol Med"},{"key":"1055_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101429","author":"L Kennedy","year":"2020","unstructured":"Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 2020;10(10):1429. https:\/\/doi.org\/10.3390\/biom10101429.","journal-title":"Biomolecules"},{"issue":"1","key":"1055_CR53","doi-asserted-by":"publisher","first-page":"9513","DOI":"10.1038\/s41598-018-27753-y","volume":"8","author":"SC Nunes","year":"2018","unstructured":"Nunes SC, Ramos C, Lopes-Coelho F, Sequeira CO, Silva F, Gouveia-Fernandes S, et al. Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Sci Rep. 2018;8(1):9513.","journal-title":"Sci Rep"},{"issue":"1","key":"1055_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/celldisc.2016.31","volume":"2","author":"H Li","year":"2016","unstructured":"Li H, Stokes W, Chater E, Roy R, De Bruin E, Hu Y, et al. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Cell Discovery. 2016;2(1):1\u201314.","journal-title":"Cell Discovery"},{"key":"1055_CR55","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/celldisc.2016.31","volume":"2","author":"H Li","year":"2016","unstructured":"Li H, Stokes W, Chater E, Roy R, de Bruin E, Hu Y, et al. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Cell Discov. 2016;2:16031.","journal-title":"Cell Discov"},{"key":"1055_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:1\u201312.","journal-title":"Cancer Metab"},{"issue":"1","key":"1055_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16503","volume":"190","author":"X Wu","year":"2020","unstructured":"Wu X, Xia J, Zhang J, Zhu Y, Wu Y, Guo J, et al. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. Br J Haematol. 2020;190(1):52\u201366.","journal-title":"Br J Haematol"},{"issue":"17","key":"1055_CR58","doi-asserted-by":"publisher","first-page":"13231","DOI":"10.18632\/oncotarget.24229","volume":"9","author":"MY Lee","year":"2018","unstructured":"Lee MY, Yeon A, Shahid M, Cho E, Sairam V, Figlin R, et al. Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. Oncotarget. 2018;9(17):13231.","journal-title":"Oncotarget"},{"key":"1055_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0458-4","volume":"13","author":"JJ van Asten","year":"2015","unstructured":"van Asten JJ, Vettukattil R, Buckle T, Rottenberg S, van Leeuwen F, Bathen TF, et al. Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. J Transl Med. 2015;13:1\u20138.","journal-title":"J Transl Med"},{"key":"1055_CR60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11060-015-1899-6","volume":"125","author":"P-D St-Coeur","year":"2015","unstructured":"St-Coeur P-D, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin PJ. Investigating a signature of Temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol. 2015;125:91\u2013102.","journal-title":"J Neurooncol"},{"issue":"1","key":"1055_CR61","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/s41598-017-09206-0","volume":"7","author":"S Dar","year":"2017","unstructured":"Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci Rep. 2017;7(1):8760.","journal-title":"Sci Rep"},{"issue":"1","key":"1055_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-019-0362-z","volume":"39","author":"X You","year":"2019","unstructured":"You X, Jiang W, Lu W, Zhang H, Yu T, Tian J, et al. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. Cancer Commun. 2019;39(1):17.","journal-title":"Cancer Commun"},{"issue":"2","key":"1055_CR63","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","volume":"158","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, et al. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol. 2009;158(2):588\u2013600.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1055_CR64","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1038\/s41598-017-05086-6","volume":"7","author":"X Li","year":"2017","unstructured":"Li X, Lu J, Kan Q, Li X, Fan Q, Li Y, et al. Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Sci Rep. 2017;7(1):5081.","journal-title":"Sci Rep"},{"key":"1055_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030623","author":"Y Chen","year":"2023","unstructured":"Chen Y, Le\u00f3n-Letelier RA, Abdel Sater AH, Vykoukal J, Dennison JB, Hanash S, et al. c-MYC-driven polyamine metabolism in ovarian cancer: from pathogenesis to early detection and therapy. Cancers (Basel). 2023;15(3):623. https:\/\/doi.org\/10.3390\/cancers15030623.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1055_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.canlet.2016.08.004","volume":"381","author":"X Zhang","year":"2016","unstructured":"Zhang X, Chen Y, Hao L, Hou A, Chen X, Li Y, et al. Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. Cancer Lett. 2016;381(2):305\u201313.","journal-title":"Cancer Lett"},{"key":"1055_CR67","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s11306-013-0517-x","volume":"9","author":"B Cao","year":"2013","unstructured":"Cao B, Li M, Zha W, Zhao Q, Gu R, Liu L, et al. Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells. Metabolomics. 2013;9:960\u201373.","journal-title":"Metabolomics"},{"issue":"3","key":"1055_CR68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3892\/or.2012.2182","volume":"29","author":"S Sasada","year":"2012","unstructured":"Sasada S, Miyata Y, Tsutani Y, Tsuyama N, Masujima T, Hihara J, Okada M. Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil. Oncol Rep. 2012;29(3):925\u201331.","journal-title":"Oncol Rep"},{"key":"1055_CR69","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jpba.2017.08.038","volume":"146","author":"RM Maria","year":"2017","unstructured":"Maria RM, Altei WF, Selistre-de-Araujo HS, Colnago LA. Impact of chemotherapy on metabolic reprogramming: characterization of the metabolic profile of breast cancer MDA-MB-231 cells using 1H HR-MAS NMR spectroscopy. J Pharm Biomed Anal. 2017;146:324\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"1055_CR70","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3892\/ijo.2016.3652","volume":"49","author":"W Wu","year":"2016","unstructured":"Wu W, Wang Q, Yin F, Yang Z, Zhang W, Gabra H, Li L. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. Int J Oncol. 2016;49(4):1651\u201365.","journal-title":"Int J Oncol"},{"issue":"2","key":"1055_CR71","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/156800911794328501","volume":"11","author":"M Montopoli","year":"2011","unstructured":"Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froldi G, et al. Metabolic reprogramming in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets. 2011;11(2):226\u201335.","journal-title":"Curr Cancer Drug Targets"},{"key":"1055_CR72","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1007\/s13277-015-4290-5","volume":"37","author":"F Lopes-Coelho","year":"2016","unstructured":"Lopes-Coelho F, Gouveia-Fernandes S, Gon\u00e7alves LG, Nunes C, Faustino I, Silva F, et al. HNF1\u03b2 drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). Tumor Biol. 2016;37:4813\u201329.","journal-title":"Tumor Biol"},{"key":"1055_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12862-018-1214-1","volume":"18","author":"SC Nunes","year":"2018","unstructured":"Nunes SC, Lopes-Coelho F, Gouveia-Fernandes S, Ramos C, Pereira SA, Serpa J. Cysteine boosters the evolutionary adaptation to CoCl 2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer. BMC Evol Biol. 2018;18:1\u201317.","journal-title":"BMC Evol Biol"},{"issue":"9","key":"1055_CR74","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1021\/acs.jproteome.6b00430","volume":"15","author":"DA Stewart","year":"2016","unstructured":"Stewart DA, Winnike JH, McRitchie SL, Clark RF, Pathmasiri WW, Sumner SJ. Metabolomics analysis of hormone-responsive and triple-negative breast cancer cell responses to Paclitaxel identify key metabolic differences. J Proteome Res. 2016;15(9):3225\u201340.","journal-title":"J Proteome Res"},{"issue":"5","key":"1055_CR75","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.3892\/ol.2017.5940","volume":"13","author":"S Lee","year":"2017","unstructured":"Lee S, Jang WJ, Choi B, Joo SH, Jeong CH. Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. Oncol Lett. 2017;13(5):3437\u201344.","journal-title":"Oncol Lett"},{"key":"1055_CR76","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11306-010-0204-0","volume":"6","author":"BJ Dewar","year":"2010","unstructured":"Dewar BJ, Keshari K, Jeffries R, Dzeja P, Graves LM, Macdonald JM. Metabolic assessment of a novel chronic myelogenous leukemic cell line and an Imatinib resistant subline by 1 H NMR spectroscopy. Metabolomics. 2010;6:439\u201350.","journal-title":"Metabolomics"},{"key":"1055_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-019-0362-z","volume":"39","author":"X You","year":"2019","unstructured":"You X, Jiang W, Lu W, Zhang H, Yu T, Tian J, et al. Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis. Cancer Commun. 2019;39:1\u201313.","journal-title":"Cancer Commun"},{"issue":"10","key":"1055_CR78","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","volume":"15","author":"DJ Kominsky","year":"2009","unstructured":"Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL\u2013positive cells. Clin Cancer Res. 2009;15(10):3442\u201350.","journal-title":"Clin Cancer Res"},{"key":"1055_CR79","doi-asserted-by":"crossref","unstructured":"Van Dang C. Cancer metabolism: The known, unknowns. 2018. p. 1.","DOI":"10.1016\/j.bbcan.2018.07.006"},{"issue":"5","key":"1055_CR80","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.","journal-title":"Sci Adv"},{"issue":"1","key":"1055_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.123","volume":"3","author":"C Mu\u00f1oz-Pinedo","year":"2012","unstructured":"Mu\u00f1oz-Pinedo C, El Mjiyad N, Ricci J-E. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3(1):e248-e.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1055_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jdsr.2017.08.003","volume":"54","author":"Y Kato","year":"2018","unstructured":"Kato Y, Maeda T, Suzuki A, Baba Y. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018;54(1):8\u201321.","journal-title":"Jpn Dent Sci Rev"},{"key":"1055_CR83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphys.2015.00382","volume":"6","author":"P Ghaffari","year":"2015","unstructured":"Ghaffari P, Mardinoglu A, Nielsen J. Cancer metabolism: a modeling perspective. Front Physiol. 2015;6:382.","journal-title":"Front Physiol"},{"issue":"2","key":"1055_CR84","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41416-019-0667-3","volume":"122","author":"C Frezza","year":"2020","unstructured":"Frezza C. Metabolism and cancer: the future is now. Br J Cancer. 2020;122(2):133\u20135.","journal-title":"Br J Cancer"},{"key":"1055_CR85","doi-asserted-by":"crossref","unstructured":"Li T, Le A. Glutamine metabolism in cancer. Heterogeneity Cancer Metabolism. 2018;1063:13\u201332.","DOI":"10.1007\/978-3-319-77736-8_2"},{"issue":"3","key":"1055_CR86","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trecan.2017.01.005","volume":"3","author":"AA Cluntun","year":"2017","unstructured":"Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3(3):169\u201380.","journal-title":"Trends Cancer"},{"key":"1055_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1509662","volume":"15","author":"H Lyu","year":"2025","unstructured":"Lyu H, Bao S, Cai L, Wang M, Liu Y, Sun Y, et al. The role and research progress of serine metabolism in tumor cells. Front Oncol. 2025;15:1509662.","journal-title":"Front Oncol"},{"issue":"10","key":"1055_CR88","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc.2016.81","volume":"16","author":"M Yang","year":"2016","unstructured":"Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16(10):650\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1055_CR89","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201907022","volume":"219","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Diaz-Meco MT, Moscat J. The complexity of the serine glycine one-carbon pathway in cancer. J Cell Biol. 2019;219(1):e201907022.","journal-title":"J Cell Biol"},{"key":"1055_CR90","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00726-011-0983-2","volume":"41","author":"F Li","year":"2011","unstructured":"Li F, Yin Y, Tan B, Kong X, Wu G. Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids. 2011;41:1185\u201393.","journal-title":"Amino Acids"},{"key":"1055_CR91","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00488.2005","author":"CS Katsanos","year":"2006","unstructured":"Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab. 2006. https:\/\/doi.org\/10.1152\/ajpendo.00488.2005.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1055_CR92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1590\/S1984-82502010000100004","volume":"46","author":"D Vianna","year":"2010","unstructured":"Vianna D, Teodoro GFR, Torres-Leal FL, Tirapegui J. Protein synthesis regulation by leucine. Braz J Pharm Sci. 2010;46:29\u201336.","journal-title":"Braz J Pharm Sci"},{"issue":"5","key":"1055_CR93","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ccr.2011.03.012","volume":"19","author":"J-H Sheen","year":"2011","unstructured":"Sheen J-H, Zoncu R, Kim D, Sabatini DM. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell. 2011;19(5):613\u201328.","journal-title":"Cancer Cell"},{"issue":"10","key":"1055_CR94","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nm.3686","volume":"20","author":"JR Mayers","year":"2014","unstructured":"Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"1055_CR95","doi-asserted-by":"publisher","first-page":"15529","DOI":"10.1038\/s41598-019-52112-w","volume":"9","author":"LR Viana","year":"2019","unstructured":"Viana LR, Tobar N, Busanello ENB, Marques AC, de Oliveira AG, Lima TI, et al. Leucine-rich diet induces a shift in tumour metabolism from glycolytic towards oxidative phosphorylation, reducing glucose consumption and metastasis in Walker-256 tumour-bearing rats. Sci Rep. 2019;9(1):15529.","journal-title":"Sci Rep"},{"issue":"39","key":"1055_CR96","doi-asserted-by":"publisher","first-page":"63679","DOI":"10.18632\/oncotarget.11626","volume":"7","author":"F Xiao","year":"2016","unstructured":"Xiao F, Wang C, Yin H, Yu J, Chen S, Fang J, Guo F. Leucine deprivation inhibits proliferation and induces apoptosis of human breast cancer cells via fatty acid synthase. Oncotarget. 2016;7(39):63679.","journal-title":"Oncotarget"},{"issue":"12","key":"1055_CR97","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1016\/j.clnu.2020.04.008","volume":"39","author":"LJ Storck","year":"2020","unstructured":"Storck LJ, Ruehlin M, Gaeumann S, Gisi D, Schmocker M, Meffert PJ, et al. Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: a randomized controlled intervention trial. Clin Nutr. 2020;39(12):3637\u201344.","journal-title":"Clin Nutr"},{"key":"1055_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1535921","volume":"12","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhang Q, Huang S, Lu Y, Peng M. Impact of ketogenic diets on cancer patient outcomes: a systematic review and meta-analysis. Front Nutr. 2025;12:1535921.","journal-title":"Front Nutr"},{"key":"1055_CR99","unstructured":"Wallis J. The Ketogenic Diet for Cancer Patients: A Narrative Review. 2018."},{"issue":"4","key":"1055_CR100","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/01635581.2019.1645864","volume":"72","author":"CW Cohen","year":"2020","unstructured":"Cohen CW, Fontaine KR, Arend RC, Gower BA. A ketogenic diet is acceptable in women with ovarian and endometrial cancer and has no adverse effects on blood lipids: a randomized, controlled trial. Nutr Cancer. 2020;72(4):584\u201394.","journal-title":"Nutr Cancer"},{"key":"1055_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/nu13031029","author":"U K\u00e4mmerer","year":"2021","unstructured":"K\u00e4mmerer U, Klement RJ, Joos FT, S\u00fctterlin M, Reuss-Borst M. Low carb and ketogenic diets increase quality of life, physical performance, body composition, and metabolic health of women with breast cancer. Nutrients. 2021;13(3):1029. https:\/\/doi.org\/10.3390\/nu13031029.","journal-title":"Nutrients"},{"issue":"1","key":"1055_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53287-y","volume":"9","author":"CM Kang","year":"2019","unstructured":"Kang CM, Yun B, Kim M, Song M, Kim YH, Lee SH, et al. Postoperative serum metabolites of patients on a low carbohydrate ketogenic diet after pancreatectomy for pancreatobiliary cancer: a nontargeted metabolomics pilot study. Sci Rep. 2019;9(1):16820.","journal-title":"Sci Rep"},{"issue":"3","key":"1055_CR103","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.clnu.2020.06.028","volume":"40","author":"A Khodabakhshi","year":"2021","unstructured":"Khodabakhshi A, Akbari ME, Mirzaei HR, Seyfried TN, Kalamian M, Davoodi SH. Effects of ketogenic metabolic therapy on patients with breast cancer: a randomized controlled clinical trial. Clin Nutr. 2021;40(3):751\u20138.","journal-title":"Clin Nutr"},{"issue":"11","key":"1055_CR104","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.21873\/anticanres.13017","volume":"38","author":"JH Ok","year":"2018","unstructured":"Ok JH, Lee H, Chung HY, Lee SH, Choi EJ, Kang CM, Lee SM. The potential use of a ketogenic diet in pancreatobiliary cancer patients after pancreatectomy. Anticancer Res. 2018;38(11):6519\u201327.","journal-title":"Anticancer Res"},{"key":"1055_CR105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neulet.2018.06.016","volume":"683","author":"Y Lu","year":"2018","unstructured":"Lu Y, Yang Y-Y, Zhou M-W, Liu N, Xing H-Y, Liu X-X, Li F. Ketogenic diet attenuates oxidative stress and inflammation after spinal cord injury by activating Nrf2 and suppressing the NF-\u03baB signaling pathways. Neurosci Lett. 2018;683:13\u20138.","journal-title":"Neurosci Lett"},{"issue":"11","key":"1055_CR106","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1128\/IAI.70.11.6294-6301.2002","volume":"70","author":"Y Osawa","year":"2002","unstructured":"Osawa Y, Nagaki M, Banno Y, Brenner DA, Asano T, Nozawa Y, et al. <article-title update=\"added\">Tumor necrosis factor alpha-induced interleukin-8 production via NF-\u03baB and phosphatidylinositol 3-kinase\/Akt pathways inhibits cell apoptosis in human hepatocytes. Infect Immun. 2002;70(11):6294\u2013301.","journal-title":"Infect Immun"},{"issue":"20","key":"1055_CR107","doi-asserted-by":"publisher","first-page":"7986","DOI":"10.1158\/0008-5472.CAN-09-2266","volume":"69","author":"C Yang","year":"2009","unstructured":"Yang C, Sudderth J, Dang T, Bachoo RG, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009;69(20):7986\u201393.","journal-title":"Cancer Res"},{"key":"1055_CR108","doi-asserted-by":"crossref","unstructured":"Kassab AE. Recent advances in targeting COX-2 for cancer therapy: a review. RSC Med Chem. 202516:2974-3002","DOI":"10.1039\/D5MD00196J"},{"key":"1055_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1099811","volume":"13","author":"K Jin","year":"2023","unstructured":"Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells. Front Oncol. 2023;13:1099811.","journal-title":"Front Oncol"},{"issue":"5","key":"1055_CR110","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/biom10050717","volume":"10","author":"H Laronha","year":"2020","unstructured":"Laronha H, Carpinteiro I, Portugal J, Azul A, Polido M, Petrova KT, et al. Challenges in matrix metalloproteinases inhibition. Biomolecules. 2020;10(5):717.","journal-title":"Biomolecules"},{"issue":"1","key":"1055_CR111","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/cancers6010366","volume":"6","author":"AH Said","year":"2014","unstructured":"Said AH, Raufman J-P, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6(1):366\u201375.","journal-title":"Cancers"},{"key":"1055_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112260","volume":"194","author":"S Mondal","year":"2020","unstructured":"Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview. Eur J Med Chem. 2020;194:112260.","journal-title":"Eur J Med Chem"},{"issue":"40","key":"1055_CR113","doi-asserted-by":"publisher","first-page":"11182","DOI":"10.1021\/acs.jafc.0c04041","volume":"68","author":"N Zhang","year":"2020","unstructured":"Zhang N, Liu C, Jin L, Zhang R, Wang T, Wang Q, et al. Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1\/M2 tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem. 2020;68(40):11182\u201396.","journal-title":"J Agric Food Chem"},{"issue":"2","key":"1055_CR114","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/hepr.12757","volume":"47","author":"H Zhang","year":"2017","unstructured":"Zhang H, Shang YP, Chen Hy, Li J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2017;47(2):149\u201359.","journal-title":"Hepatol Res"},{"issue":"2","key":"1055_CR115","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm.2016.140","volume":"18","author":"BR Sabari","year":"2017","unstructured":"Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18(2):90\u2013101.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1055_CR116","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30\u20139.","journal-title":"J Clin Invest"},{"issue":"3","key":"1055_CR117","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41419-019-1463-y","volume":"10","author":"K Liu","year":"2019","unstructured":"Liu K, Li F, Sun Q, Lin N, Han H, You K, et al. P53 \u03b2-hydroxybutyrylation attenuates p53 activity. Cell Death Dis. 2019;10(3):243.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1055_CR118","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1113\/jphysiol.2006.108324","volume":"574","author":"H Motoshima","year":"2006","unstructured":"Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation\u2013AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006;574(1):63\u201371.","journal-title":"J Physiol"},{"key":"1055_CR119","first-page":"26","volume":"203","author":"Z Wang","year":"2016","unstructured":"Wang Z, Wang N, Liu P, Xie X. AMPK and cancer. AMP-activated Protein Kinase. 2016;203:26.","journal-title":"AMP-activated Protein Kinase"},{"issue":"3","key":"1055_CR120","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3858\/emm.2009.41.3.023","volume":"41","author":"Y-K Lee","year":"2009","unstructured":"Lee Y-K, Park SY, Kim Y-M, Lee WS, Park OJ. AMP kinase\/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with Quercetin. Exp Mol Med. 2009;41(3):201\u20137.","journal-title":"Exp Mol Med"},{"issue":"25","key":"1055_CR121","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.2174\/0929867324666170713150440","volume":"23","author":"S Umezawa","year":"2017","unstructured":"Umezawa S, Higurashi T, Nakajima A. AMPK: therapeutic target for diabetes and cancer prevention. Curr Pharm Des. 2017;23(25):3629\u201344.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"1055_CR122","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.molcel.2020.05.018","volume":"78","author":"S Bose","year":"2020","unstructured":"Bose S, Allen AE, Locasale JW. The molecular link from diet to cancer cell metabolism. Mol Cell. 2020;78(6):1034\u201344.","journal-title":"Mol Cell"},{"key":"1055_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087268","author":"L Pekarek","year":"2023","unstructured":"Pekarek L, Torres-Carranza D, Fraile-Martinez O, Garc\u00eda-Montero C, Pekarek T, Saez MA, et al. An overview of the role of MicroRNAs on carcinogenesis: a focus on cell cycle, angiogenesis and metastasis. Int J Mol Sci. 2023;24(8):7268. https:\/\/doi.org\/10.3390\/ijms24087268.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1055_CR124","volume":"2016","author":"A Loboda","year":"2016","unstructured":"Loboda A, Sobczak M, Jozkowicz A, Dulak J. TGF-\u03b21\/Smads and miR\u201021 in renal fibrosis and inflammation. Mediators Inflamm. 2016;2016(1):8319283.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"1055_CR125","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ejso.2011.04.001","volume":"37","author":"K Chang","year":"2011","unstructured":"Chang K, Miller N, Kheirelseid E, Ingoldsby H, Hennessy E, Curran C, et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. European Journal of Surgical Oncology (EJSO). 2011;37(7):597\u2013603.","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"key":"1055_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-374","volume":"9","author":"GM Arndt","year":"2009","unstructured":"Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global MicroRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009;9:1\u201317.","journal-title":"BMC Cancer"},{"issue":"40","key":"1055_CR127","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1038\/onc.2011.131","volume":"30","author":"C King","year":"2011","unstructured":"King C, Wang L, Winograd R, Madison B, Mongroo P, Johnstone C, Rustgi AK. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and-independent mechanisms. Oncogene. 2011;30(40):4185\u201393.","journal-title":"Oncogene"},{"issue":"12","key":"1055_CR128","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-14-0069","volume":"20","author":"D Sha","year":"2014","unstructured":"Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, et al. Association study of the let-7 miRNA-complementary site variant in the 3\u2032 untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial). Clin Cancer Res. 2014;20(12):3319\u201327.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1055_CR129","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ijc.28522","volume":"134","author":"N Oue","year":"2014","unstructured":"Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer. 2014;134(8):1926\u201334.","journal-title":"Int J Cancer"},{"issue":"1","key":"1055_CR130","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s42003-019-0455-x","volume":"2","author":"P Mukherjee","year":"2019","unstructured":"Mukherjee P, Augur ZM, Li M, Hill C, Greenwood B, Domin MA, et al. Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma. Commun Biology. 2019;2(1):200.","journal-title":"Commun Biology"},{"key":"1055_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-017-0398-9","volume":"24","author":"I Mart\u00ednez-Reza","year":"2017","unstructured":"Mart\u00ednez-Reza I, D\u00edaz L, Garc\u00eda-Becerra R. Preclinical and clinical aspects of TNF-\u03b1 and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci. 2017;24:1\u20138.","journal-title":"J Biomed Sci"},{"key":"1055_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/nu14224932","author":"CY Hwang","year":"2022","unstructured":"Hwang CY, Choe W, Yoon KS, Ha J, Kim SS, Yeo EJ, et al. Molecular mechanisms for ketone body metabolism, signaling functions, and therapeutic potential in cancer. Nutrients. 2022;14(22):4932. https:\/\/doi.org\/10.3390\/nu14224932.","journal-title":"Nutrients"},{"key":"1055_CR133","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11154-020-09567-4","volume":"21","author":"B Bandera-Merchan","year":"2020","unstructured":"Bandera-Merchan B, Boughanem H, Crujeiras AB, Macias-Gonzalez M, Tinahones FJ. Ketotherapy as an epigenetic modifier in cancer. Rev Endocr Metab Disord. 2020;21:509\u201319.","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"1055_CR134","first-page":"260","volume":"21","author":"H-B Ruan","year":"2018","unstructured":"Ruan H-B, Crawford PA. Ketone bodies as epigenetic modifiers. Curr Opin Clin Nutr Metab Care. 2018;21(4):260\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1055_CR135","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-1-4614-6819-6_14","volume-title":"Obesity, Inflammation and Cancer","author":"SD Hursting","year":"2013","unstructured":"Hursting SD, Ford NA, Dunlap SM, Hursting MJ, Lashinger LM. Calorie restriction and cancer prevention: established and emerging mechanisms. In: Obesity, Inflammation and Cancer. Springer; 2013. p. 363\u201379."},{"key":"1055_CR136","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3389\/fimmu.2018.02649","volume":"9","author":"Y Duan","year":"2018","unstructured":"Duan Y, Zeng L, Zheng C, Song B, Li F, Kong X, Xu K. Inflammatory links between high fat diets and diseases. Front Immunol. 2018;9:2649.","journal-title":"Front Immunol"},{"issue":"10","key":"1055_CR137","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102519","volume":"20","author":"S Parida","year":"2019","unstructured":"Parida S, Siddharth S, Sharma D. Adiponectin, obesity, and cancer: clash of the bigwigs in health and disease. Int J Mol Sci. 2019;20(10):2519.","journal-title":"Int J Mol Sci"},{"key":"1055_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.594408","volume":"8","author":"J Li","year":"2021","unstructured":"Li J, Zhang H, Dai Z. Cancer treatment with the ketogenic diet: a systematic review and meta-analysis of animal studies. Front Nutr. 2021;8:594408.","journal-title":"Front Nutr"},{"issue":"10","key":"1055_CR139","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1158\/0008-5472.CAN-23-2742","volume":"84","author":"S Murphy","year":"2024","unstructured":"Murphy S, Rahmy S, Gan D, Liu G, Zhu Y, Manyak M, et al. Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy. Cancer Res. 2024;84(10):1597\u2013612.","journal-title":"Cancer Res"},{"issue":"1","key":"1055_CR140","doi-asserted-by":"publisher","first-page":"e0296523","DOI":"10.1371\/journal.pone.0296523","volume":"19","author":"A Buga","year":"2024","unstructured":"Buga A, Harper DG, Sapper TN, Hyde PN, Fell B, Dickerson R, et al. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: the Keto-CARE trial. PLoS One. 2024;19(1):e0296523.","journal-title":"PLoS One"},{"key":"1055_CR141","doi-asserted-by":"publisher","first-page":"110659","DOI":"10.1016\/j.nut.2019.110659","volume":"72","author":"WH Talib","year":"2020","unstructured":"Talib WH. A ketogenic diet combined with melatonin overcomes cisplatin and vincristine drug resistance in breast carcinoma syngraft. Nutrition. 2020;72:110659.","journal-title":"Nutrition"},{"issue":"3","key":"1055_CR142","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jhep.2014.10.024","volume":"62","author":"ME Healy","year":"2015","unstructured":"Healy ME, Chow JD, Byrne FL, Breen DS, Leitinger N, Li C, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol. 2015;62(3):599\u2013606.","journal-title":"J Hepatol"},{"issue":"9","key":"1055_CR143","doi-asserted-by":"publisher","first-page":"e108444","DOI":"10.1371\/journal.pone.0108444","volume":"9","author":"Y Zhuang","year":"2014","unstructured":"Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of Metformin to cancer cells both in vitro and in vivo. PLoS One. 2014;9(9):e108444.","journal-title":"PLoS One"},{"issue":"2","key":"1055_CR144","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/nu10020206","volume":"10","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Tonouchi H, Sasayama A, Ashida K. A ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients. 2018;10(2):206.","journal-title":"Nutrients"},{"issue":"4","key":"1055_CR145","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1194\/jlr.M082040","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Jia P-P, Liu Q-L, Cong M-H, Gao Y, Shi H-P, et al. Low ketolytic enzyme levels in tumors predict ketogenic diet responses in cancer cell lines in vitro and in vivo. J Lipid Res. 2018;59(4):625\u201334.","journal-title":"J Lipid Res"},{"key":"1055_CR146","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/1471-2407-11-315","volume":"11","author":"GD Maurer","year":"2011","unstructured":"Maurer GD, Brucker DP, B\u00e4hr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315.","journal-title":"BMC Cancer"},{"issue":"3","key":"1055_CR147","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3164\/jcbn.18-103","volume":"64","author":"E Kasumi","year":"2019","unstructured":"Kasumi E, Sato N. A ketogenic diet improves the prognosis in a mouse model of peritoneal dissemination without tumor regression. J Clin Biochem Nutr. 2019;64(3):201\u20138.","journal-title":"J Clin Biochem Nutr"},{"issue":"23","key":"1055_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adm9481","volume":"10","author":"Z Su","year":"2024","unstructured":"Su Z, Liu Y, Xia Z, Rustgi AK, Gu W. An unexpected role for the ketogenic diet in triggering tumor metastasis by modulating BACH1-mediated transcription. Sci Adv. 2024;10(23):eadm9481.","journal-title":"Sci Adv"},{"key":"1055_CR149","doi-asserted-by":"crossref","unstructured":"Ferrer M, Mourikis N, Davidson EE, Kleeman SO, Zaccaria M, Habel J et al. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Cell Metab. 2023;35(7):1147-62.e7.","DOI":"10.1016\/j.cmet.2023.05.008"},{"key":"1055_CR150","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8105735","volume":"2020","author":"Q Tran","year":"2020","unstructured":"Tran Q, Lee H, Kim C, Kong G, Gong N, Kwon SH, et al. Revisiting the Warburg Effect: diet-based strategies for cancer prevention. Biomed Res Int. 2020;2020:8105735.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1055_CR151","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jn\/nxz308","volume":"150","author":"DS Ludwig","year":"2020","unstructured":"Ludwig DS. The ketogenic diet: evidence for optimism but High-Quality research needed. J Nutr. 2020;150(6):1354\u20139.","journal-title":"J Nutr"},{"issue":"4","key":"1055_CR152","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/CEJ.0000000000000918","volume":"34","author":"Q Deng","year":"2025","unstructured":"Deng Q, Lv R, Zou T. The effects of the ketogenic diet on cancer treatment: a narrative review. Eur J Cancer Prev. 2025;34(4):291\u2013300.","journal-title":"Eur J Cancer Prev"},{"issue":"8","key":"1055_CR153","first-page":"e9639","volume":"12","author":"JT Batch","year":"2020","unstructured":"Batch JT, Lamsal SP, Adkins M, Sultan S, Ramirez MN. Advantages and disadvantages of the ketogenic diet: a review article. Cureus. 2020;12(8):e9639.","journal-title":"Cureus"},{"key":"1055_CR154","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.molmet.2019.06.026","volume":"33","author":"DD Weber","year":"2020","unstructured":"Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer - where do we stand? Mol Metab. 2020;33:102\u201321.","journal-title":"Mol Metab"},{"key":"1055_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102334","author":"R Egashira","year":"2023","unstructured":"Egashira R, Matsunaga M, Miyake A, Hotta S, Nagai N, Yamaguchi C, et al. Long-term effects of a ketogenic diet for cancer. Nutrients. 2023;15(10):2334. https:\/\/doi.org\/10.3390\/nu15102334.","journal-title":"Nutrients"},{"issue":"9","key":"1055_CR156","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/14737140.2025.2522936","volume":"25","author":"RJ Klement","year":"2025","unstructured":"Klement RJ. Is the ketogenic diet still controversial in cancer treatment? Expert Rev Anticancer Ther. 2025;25(9):993\u20137.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"1055_CR157","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12916-024-03775-4","volume":"22","author":"T Duraj","year":"2024","unstructured":"Duraj T, Kalamian M, Zuccoli G, Maroon JC, D\u2019Agostino DP, Scheck AC, et al. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med. 2024;22(1):578.","journal-title":"BMC Med"},{"key":"1055_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1432717","volume":"11","author":"A Zemer","year":"2024","unstructured":"Zemer A, Samaei S, Yoel U, Biderman A, Pincu Y. Ketogenic diet in clinical populations\u2014a narrative review. Front Med (Lausanne). 2024;11:1432717.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"1055_CR159","first-page":"5243","volume":"28","author":"PN Klassen","year":"2020","unstructured":"Klassen PN, Goldenberg BA, Lambert P, Vagianos K, Kim CA. Ketogenic and low-sugar diets for patients with cancer: perceptions and practices of medical oncologists in Canada. Support Care Cancer. 2020;28(11):5243\u20139.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1055_CR160","first-page":"106","volume":"69","author":"L Schmidt","year":"2022","unstructured":"Schmidt L, Mathies V, von Grundherr J, Rubin D, H\u00fcbner J, for the Working Group Prevention and Integrative Oncology in the German Cancer Society and the German Society for Nutritional Medicine. Ketogenic and low-carbohydrate diets in people with cancer. A statement by the working group on prevention and integrative oncology (PRIO) in the German cancer society (GCS) and the German society for nutritional medicine (DGEM). Ernahrungsumschau. 2022;69(7):106\u201311.","journal-title":"Ernahrungsumschau"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-01055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-025-01055-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-025-01055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:15:16Z","timestamp":1781622916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12986-025-01055-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":160,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1186\/s12986-025-01055-3","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any animal or human experimental models. Hence, ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}